Recurrent High Grade Ovarian Serous Adenocarcinoma
3 clinical trials · Condition
◉ Watch Recurrent High Grade Ovarian Serous Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients (NCT05114421) | M.D. Anderson Cancer Center | 2021-11-09 |
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (NCT03610490) | M.D. Anderson Cancer Center | 2018-10-16 |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (NCT02898207) | National Cancer Institute (NCI) | 2017-05-19 |
Track Recurrent High Grade Ovarian Serous Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.